Skip to main content
FDC · Health Care · 2026-08-07

F D C Ltd

3.2WatchWeak -0.2Stage 2 · wk 4In scan: Prop Scan · Breakout WatchMARKET: BULL TOPPING · 2026-08-07
₹369.8
-0.05% today
₹6,021 Cr · Mid cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured ORS powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Vitcofol, Ziglim, Ziglim-M,Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Electral, and Enerzal brands. It also exports its products to approximately 50 countries. FDC Limited was founded in 1936 and is based in Mumbai, India.

Visit company website →
P/E (TTM)
32.3
Forward 18.4
Earnings Growth (YoY)
-23.7%
Revenue +0.1%
Dividend Yield
2.48%
P/B 2.9
vs 52W High
-23.1%
₹321.1 lo₹480.7 hi
23.1% below 52W high — deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 4
1w13w26w
Week 4 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
-5.2%
200 DMA: ₹390.1 · sloping down
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.60x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
MA20 rolling over · -3.5% vs MA50 +3.5%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
This stock ranks #74 of 79 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Ranks #48 of 53 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-15 → 2026-08-07
S2 23w
S2 51w
S4 15w
S4 27w
2023-05-152026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 1w → S2 23w → S3 4w → S2 51w → S3 10w → S4 15w → S1 9w → S2 8w → S3 9w → S4 27w → S1 7w → S2 4w current
Total tracked: 168 weeks across 12 stage runs.
1M
-14.4%
3M
-2.7%
6M
-0.6%
YTD
-11.9%
1Y
-22.8%
Scan Membership
Prop Scan
Latest: 2026-07-31
Breakout Watch
Latest: 2026-07-14
16 appearances in last 60 days. First seen: 2025-07-21.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S2
Wk 4 · Vol x
2026-08-06S2
Wk 4 · Vol x
2026-08-05S2
Wk 4 · Vol x
2026-08-04S2
Wk 4 · Vol x
2026-08-03S2
Wk 3 · Vol x
2026-07-31S2
Wk 3 · Vol x
2026-07-30S2
Wk 3 · Vol x
2026-07-29S2
Wk 3 · Vol x
2026-07-28S2
Wk 3 · Vol x
2026-07-27S2
Wk 2 · Vol x
2026-07-24S2
Wk 2 · Vol x
2026-07-23S2
Wk 2 · Vol x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹406.1
200 DMA
₹390.1
52W High
₹480.7
52W Low
₹321.1
5D Low
₹369.8
Resistance levels (recent highs)
20d High
₹428
60d High
₹434.3
120d High
₹434.3
250d High
₹480.7
Next resistance
+15.7%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.